Citius Pharmaceuticals, Inc. (CTXR)
Stock Price:
$1.02 USD
0.00 (0.00%)
Updated Oct 27, 2020 1:42 PM EDT - Market open
Key Info
| Market Cap |
47.24M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-17.08M |
| Shares Out |
46.32M |
| EPS (ttm) |
-0.54 |
| PE Ratio |
n/a |
| Forward PE |
2.82 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 27, 2020 |
| Last Price |
$1.02 |
| Previous Close |
$1.02 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
1.02 |
| Day's Range |
1.01 - 1.03 |
| Day's Volume |
184,811 |
| 52-Week Range |
0.40 - 1.97 |
More Stats
| Market Cap |
47.24M |
| Enterprise Value |
40.06M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
46.32M |
| Float |
34.74M |
| EPS (basic) |
-0.55 |
| EPS (diluted) |
-0.54 |
| FCF / Share |
-0.40 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
809,120 |
| Short Ratio |
0.89 |
| Short % of Float |
2.33% |
| Beta |
1.10 |
| PE Ratio |
n/a |
| Forward PE |
2.82 |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.12 |
| Revenue |
n/a |
| Operating Income |
-17.23M |
| Net Income |
-17.08M |
| Free Cash Flow |
-16.48M |
| Net Cash |
7.18M |
| Net Cash / Share |
0.16 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-33.68% |
| ROE |
-67.97% |
| ROIC |
-97.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$5.50*
(439.22% upside)
Low
4.00
Current: $1.02
High
7.00
Target: 5.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 | 2012 |
|---|
| Revenue | - | - | - | - | - | - | - |
| Operating Income | -15.60 | -13.79 | -9.99 | -7.45 | -3.23 | -1.18 | -1.02 |
| Net Income | -15.56 | -12.54 | -10.38 | -8.30 | -2.90 | -1.29 | -1.05 |
| Shares Outstanding | 20.16 | 10.73 | 5.48 | 3.62 | 2.12 | 1.18 | 1.13 |
| Earnings Per Share | -0.77 | -1.17 | -1.89 | -2.29 | -1.37 | -1.05 | -0.90 |
| Operating Cash Flow | -12.44 | -11.32 | -7.97 | -5.90 | -2.39 | -1.10 | -0.92 |
| Capital Expenditures | - | - | - | - | - | - | - |
| Free Cash Flow | -12.44 | -11.32 | -7.97 | -5.90 | -2.39 | -1.10 | -0.92 |
| Cash & Equivalents | 7.95 | 9.19 | 3.21 | 0.30 | 0.68 | 0.05 | - |
| Total Debt | 0.17 | 0.17 | 0.17 | 0.67 | - | 2.64 | - |
| Net Cash / Debt | 7.78 | 9.01 | 3.03 | -0.38 | 0.68 | -2.58 | - |
| Assets | 36.75 | 31.05 | 24.42 | 21.95 | 0.74 | 0.11 | - |
| Liabilities | 9.59 | 3.18 | 2.47 | 5.18 | 1.38 | 3.01 | - |
| Book Value | 27.15 | 27.87 | 21.95 | 16.77 | -0.64 | -2.90 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Citius Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
9 |
| CEO |
Myron Z. Holubiak |
Stock Information
| Ticker Symbol |
CTXR |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CTXR |
Description
Citius Pharmaceuticals, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction tissue expander infections following breast reconstructive surgeries; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.